Therefore, the therapeutic potential of disrupting the interaction between MDM2 and P53 has been intensely studied in tumors harboring an MDM2 amplification, and small-molecule inhibitors such as Nutlin-3a demonstrate a successful reactivation of the P53-dependent apoptosis in osteosarcoma, colon cancer, and GCTs [28,41,200,201,202,203]. This evidence concerns the gene TP53 and malignant colon neoplasm.